Alkermes

Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress

AnalystLowTarget

Not Invested

Consensus Narrative from 16 Analysts

Published

30 Apr 25

Updated

09 Aug 25

AnalystLowTarget's Fair Value

US$30.00

8.6% undervalued

09 Aug

US$27.43

3.8%

3.1%

Author's Valuation

US$30.0

8.6% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Decreased 0.83%

AnalystLowTarget made no meaningful changes to valuation assumptions.

AnalystLowTarget Fair Value

US$30.0

8.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.30%

Biotech revenue growth rate

11.40%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.16%

Calculation

US$183.14m

Earnings '28

33.46x

PE Ratio '28

US$6.13b

Market Cap '28

US$6.13b

Market Cap '28

166.31m

No. shares '28

US$36.85

Share Price '28

US$36.85 Share Price '28

Discounted to 2025 @ 7.16% p.a.

US$29.94

Fair Value '25

Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress

Shared on07 May 25Fair value Decreased 0.83%

Shared on07 May 25
Fair value Decreased 0.83%